Wilson celebrates the first U.S. patient to complete gene therapy for sickle cell, but says advocacy must continue.

High-yield dividend stocks have been gaining momentum ahead of potential Fed rate cuts. Here's why these two high-yield ...

Patient enrollment and site activation progressing in Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― Ended the third quarter of 2024 with $257.2 million in cash, cash equivalents ...

When Pfizer acquired Global Blood Therapeutics in October 2022, the flagship drug in the company’s portfolio was Oxbryta, a groundbreaking treatment that targets the root cause of sickle cell ...

Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Good morning, and welcome to Fulcrum Therapeutics Third Quarter ...

Andrew Fein, an analyst from H.C. Wainwright, reiterated the Hold rating on Fulcrum Therapeutics (FULC – Research Report). The associated ...

Sickle cell patient files lawsuit against Global Blood Therapeutics, a wholly owned subsidiary of Pfizer, alleging harm from medication. The lawsuit, filed on Hardiman's behalf by the law firm ...

Oxbryta, approved in 2019 to treat sickle cell disease, was intended to reduce pain and improve red blood cell health. However, recent clinical trials revealed that the drug was linked to ...

Detailed price information for Fulcrum Therapeutics Inc (FULC-Q) from The Globe and Mail including charting and trades.

COURT: N.D. Cal. TRACK DOCKET: No. 3:24-cv-07786 (Bloomberg Law subscription) Pfizer Inc. and its subsidiary Global Blood Therapeutics Inc. should have known that their now-recalled treatment for ...